

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived mouse IL-12 R beta 2 protein		
	Mouse IL-12 R β 2 (Met1-Asn637) Accession # P97378	IEGRMDP	Mouse IgG _{2A} (Glu98-Lys330)
	N-terminus		C-terminus
N-terminal Sequence	Asn24		
Analysis			
Structure / Form	Disulfide-linked homodimer		
Predicted Molecular Mass	95.7 kDa (monomer)		

SPECIFICATIONS

SDS-PAGE	125-145 kDa, reducing conditions
Activity	Measured by its binding ability in a functional ELISA. When Recombinant Mouse (rm) IL-12 R β 2 Fc Chimera is immobilized at 0.5 μ g/mL (100 μ L/well), the concentration of rmlIL-12 that produces 50% of the optimal binding response is found to be approximately 4 - 20 ng/mL.
Endotoxin Level	<0.10 EU per 1 μ g of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 μ g/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

The high-affinity IL-12 receptor complex includes the 100 kDa IL-12 receptor β 1 (IL-12 R β 1) and the 130 kDa IL-12 Receptor β 2 (IL-12 R β 2) subunits, both of which are type I transmembrane proteins that belong to the cytokine receptor superfamily (1, 2). The complex's ligand, IL-12, is a disulfide-linked heterodimer composed of 35 kDa (IL-12 α p35) and 40 kDa (IL-12 β p40) subunits. IL-12 R β 2 binds IL-12 α and signals through Jak2, while IL-12 R β 1 binds IL-12 β and signals through Tyk2 (3). IL-12 R β 1 is also a subunit of the IL-23 receptor complex (3). The 874 amino acid (aa) mouse IL-12 R β 2 precursor includes a 23 aa signal peptide, a 614 aa extracellular domain (ECD), a 21 aa transmembrane segment and a 216 aa cytoplasmic region. The ECD possesses one C2-type Ig-like domain, five fibronectin type III (Fn III) repeats, 14 potential N-glycosylation sites, and a WSXWS motif, while the cytoplasmic region contains a Box 1 motif and three tyrosine phosphorylation sites that presumably mediate intracellular signaling (3). The mouse IL-12 R β 2 ECD shares 91% aa sequence identity with rat IL-12 R β 2, and 68% with human, porcine and bovine IL-12 R β 2. Human and mouse IL-12 R β 2 do not bind cross-species IL-12 (2). A 734 aa mouse isoform that lacks aa 363-503 within the Fn III domains is reported (4). Unlike IL-12 R β 1, which is constitutively expressed on T cells, NK cells and B cells, IL-12 R β 2 expression is more restricted (2). On naïve T cells, IL-12 R β 2 is expressed following STAT1 activation by IFN- γ , IL-27 and/or T cell receptor ligation. This up-regulation allows IL-12 to promote Th1, but not Th2, differentiation (5-7). Among B cells, surface expression is limited to naïve germinal center and memory B cells, and myeloma cells (2). Deletion of IL-12 R β 2 causes systemic over-expression of IL-6, accelerated maturation of thymocytes, deficient regulatory T cell maturation and function, and reduced splenic T cell apoptosis (2, 8-10). These mice are susceptible to autoimmune diseases such as experimental autoimmune encephalitis and spontaneous B cell malignancies (2, 8-10). In humans, polymorphism of the IL-12 R β 2 gene is associated with systemic sclerosis (11).

References:

1. Presky, D.H. *et al.* (1996) Proc. Natl. Acad. Sci. USA **93**:14002.
2. Pistoia, V. *et al.* (2009) J. Clin. Oncol. **27**:4809.
3. Zou, J. *et al.* (1997) J. Biol. Chem. **272**:6073.
4. GenBank protein Accession # P97378.
5. Rogge, L. *et al.* (1997) J. Exp. Med. **185**:825.
6. Becskei, A. and M.J. Grusby (2007) FEBS Lett. **581**:5199.
7. Szabo, S.J. *et al.* (1997) J. Exp. Med. **185**:817.
8. Zhao, Z. *et al.* (2008) J. Immunol. **181**:3870.
9. Gran, B. *et al.* (2010) Exp. Mol. Pathol. **89**:126.
10. Airoidi, I. *et al.* (2005) Blood **106**:3846.
11. Bossini-Castillo, L. *et al.* (2011) Hum. Mol. Genet. Nov. 29 [Epub ahead of print].